Teriflunomide

特立氟胺

Report date: 2024/03/12 09:10:35
NME

Base Information

Drug NameTeriflunomide
Drug Alias NameTeriflunomidumTeriflunomidaAubagio奥巴捷HMR-1726 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydroorotate dehydrogenase inhibitors
TargetsDihydroorotate dehydrogenase
Therapy Area/IndicationsSpinal Cord DiseasesMultiple SclerosisParaparesis, Tropical Spastic
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2012/09/12
Country/TerritoryCzechiaBelgiumBulgaria +[47] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofiGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesSanofi Us Services IncNational Institute Of Neurological Disorders And StrokeGenzyme Corp +[7] 
Inactive CompaniesSanofi
Active IndicationsSpinal Cord DiseasesMultiple SclerosisParaparesis, Tropical Spastic
Inactive IndicationsN/A

Other Information

ATC CodeL04AK02
Related LinksWikipediaDrugBankKEGG